Evaluation of the Effect of a Probiotic in Patients Undergoing Orthodontic Therapy
1 other identifier
interventional
60
1 country
1
Brief Summary
Orthodontic patients need supplementary oral hygiene tools in addition to professional oral hygiene. The aim of this study is to evaluate the effects of Bifidobacterium animalis subs. Lactis HN019 on plaque accumulation and gingival bleeding in orthodontic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 20, 2024
CompletedFirst Posted
Study publicly available on registry
December 30, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedOctober 1, 2025
September 1, 2025
6 months
December 20, 2024
September 30, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Full Mouth Bleeding Score (FMBS)
FMBS is a dichotomous index indicating the presence of gingival bleeding on 6 surfaces, the same as FMPS, after light probing. The ratio of surfaces with bleeding to the total of the assessed surfaces is presented as a percentage.
4 months
Secondary Outcomes (1)
Full Mouth Plaque Score (FMPS)
4 months
Study Arms (2)
Domiciliary oral hygiene with probiotics
EXPERIMENTALDuring the first sitting (T0), after checking the inclusion criteria to enter the re-search protocol, a professional oral hygiene session is carried out through the use of ultrasonic inserts, hand instruments, and glycine powder. One month after the first session (T1), FMPS and FMBS are detected. Probiotic administration is discontinued in patients belonging to the test group. At 2 months from baseline (T2), plaque and bleeding indices are recalculated and, for test group patients only, probiotic supply is delivered for 1 month. Then, after 1 month (T3), plaque and bleeding indices are measured and probiotic supply is discontinued.
Domiciliary oral hygiene alone
NO INTERVENTIONDuring the first sitting (T0), after checking the inclusion criteria to enter the re-search protocol, a professional oral hygiene session is carried out through the use of ultrasonic inserts, hand instruments, and glycine powder. All patient is instructed to perform home oral hygiene procedures using a medium-bristle manual toothbrush and fluoride toothpaste (1450 ppm F) with no added anti-plaque or anti-calculus property. Patients are advised against the use of any mouthwash.
Interventions
The probiotic used in the study is Bifidobacterium Lactis HN019, distributed com-mercially in Italy by Curasept (Curasept Prevent®, Curasept S.p.A., Saronno, VA, Italy), with added Kluyveromyces Marxianus Fragilis B0399, colostrum and biotin. The probiotic was taken by patients following the manufacturer's directions via 2 chewable tablets daily, morning and evening, after normal daily oral hygiene, achieving daily average values of B. Lactis HN019 of 2\*107 CFU and Kluyveromyces marxianus fragilis B0399 of 2\*109 CFU.
Eligibility Criteria
You may qualify if:
- age range of 10 to 30 years old;
- good general health;
- patients undergoing fixed multibracket orthodontic treatment;
- patients undergoing invisible aligner orthodontic treatment.
You may not qualify if:
- physical, mental or motor disabilities;
- systemic conditions that influence the progression of gingivitis;
- presence of non-plaque-induced gingivitis;
- known allergies;
- smokers (if more than 5 cigarettes per day);
- use of antibiotics, anti-inflammatories, or probiotics in the 6 months prior to recruitment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AOU Città della Salute e della Scienza
Torino, Italy, 10126, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Masking Details
- The operator performing the data collection was unaware of the group membership of the evaluated patient
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dental Hygienist
Study Record Dates
First Submitted
December 20, 2024
First Posted
December 30, 2024
Study Start
January 1, 2025
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
October 1, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
IPD will shared by papers or presentations